The association between prucalopride efficacy and constipation type

Jadav, A. M.; McMullin, C.; Smith, J H; Chapple, Keith; Brown, S. R.

doi:10.1007/s10151-013-1017-8

Cited by 22 publications

(16 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Tegaserod, a partial agonist at the 5-HT4 receptor, marketed for short term treatment of IBS, was withdrawn recently due to cardiovascular complications. Another related compound prucalopride recently demonstrated superior efficacy and generally minor side effects, headache being the most common [40]. However, in a recent clinical trial the efficacy of prucalopride was not statistically significantly different relative to a placebo [41].…”

Section: Management Of Ibsmentioning

confidence: 99%

Irritable Bowel Syndrome: Clinical Manifestations, Dietary Influences, and Management

et al. 2017

View full text Add to dashboard Cite

Irritable bowel syndrome (IBS) is a functional gastrointestinal disorder that is characterized by symptoms of chronic abdominal pain and altered bowel habits in the absence of an overtly identifiable cause. It is the most commonly diagnosed functional gastrointestinal disorder, accounting for about one third of gastroenterology visits. It generally presents as a complex of symptoms, including psychological dysfunction. Hypersensitivity to certain foods, especially foods that contain high amounts of fructose, plays a role in the pathophysiology of IBS. Elevated consumption of high-fructose corn syrup (HFCS) has been discussed in this aspect. The treatment options for IBS are challenging and varied. In addition to dietary restrictions for HFCS-induced IBS, such as low-FODMAP (Fermentable Oligosaccharides, Disaccharide, Monosaccharides, and Polyols) diets, existing drug therapies are administered based on the predominant symptoms and IBS-subtype. Patients with IBS are likely to suffer from issues, such as anxiety, depression, and post-traumatic-stress disorder. Biopsychosocial factors particularly socioeconomic status, sex, and race should, thus, be considered for diagnostic evaluation of patients with IBS.

show abstract

Section: Management Of Ibsmentioning

confidence: 99%

Irritable Bowel Syndrome: Clinical Manifestations, Dietary Influences, and Management

et al. 2017

View full text Add to dashboard Cite

show abstract

“…Prucalopride is a 5-HT 4 receptor agonist that accelerates colonic transit and improves constipation symptoms [16]. A recent meta-analysis that included 11 randomized controlled trials showed significant improvement in the number of CSBMs in response to treatment with prucalopride.…”

Section: Prucalopridementioning

confidence: 99%

New and Investigational Agents for Irritable Bowel Syndrome

Wadhwa

Camilleri²,

Grover³

2015

Curr Gastroenterol Rep

View full text Add to dashboard Cite

Irritable bowel syndrome (IBS) affects about 15 % of the US population and results in significant morbidity and health care costs. There remains a significant unmet need for effective treatments particularly for the pain component of IBS and other functional gastrointestinal disorders (FGIDs). Progress made in our understanding of pathophysiological mechanisms such as the role of altered bile acid metabolism, neurohormonal regulation, immune dysfunction, the epithelial barrier and secretory properties of the gut has led to advancements in therapeutic armamentarium for IBS. This review discusses the new drugs for constipation and diarrhea-predominant IBS subtypes that have been tested or have been under investigation over the last 3-4 years. Overall, there is a promising pipeline of investigational drugs for the future treatment of IBS and related FGIDs.

show abstract

“…Prucalopride is a selective 5-HT 4 receptor agonist with prokinetic activity that is known to accelerate colonic transit and improve constipation related complaints. 68 Prucalopride stimulates high-amplitude propagated contractions and increases segmental contractions, which are likely to be the under-lying mechanisms of its effects on bowel habits. 69 Three trials (which assessed 620, 641 and 713 patients, respectively) examining the use of prucalopride in CC demonstrated a significant increase in the proportion of patients achieving at least 3 SBMs per week compared with placebo.…”

Section: Serotonin Receptor Modulatorsmentioning

confidence: 99%

Emerging Pharmacologic Therapies for Constipation-predominant Irritable Bowel Syndrome and Chronic Constipation

Eswaran¹,

Guentner²,

Chey³

2014

J Neurogastroenterol Motil

View full text Add to dashboard Cite

Irritable bowel syndrome with constipation and chronic functional constipation are common digestive disorders that negatively impact quality of life and account for billions of dollars in health care costs. Related to the heterogeneity of pathogenesis that underlie these disorders and the failure of symptoms to reliably predict underlying pathophysiology, traditional therapies provide relief to only a subset of affected individuals. The evidence surrounding new and emerging pharmacologic treatments, which include both luminally and systemically acting drugs, is discussed here. These include agents such as lubiprostone, bile acid modulations, guanylate cyclase-C receptor agonists, serotonin receptor modulators and herbal therapies.

show abstract

The association between prucalopride efficacy and constipation type

Abstract: Patients with all categories of constipation may respond to prucalopride. A trial regime may be indicated regardless of the aetiology of the constipation.

Cited by 22 publications

References 23 publications

Irritable Bowel Syndrome: Clinical Manifestations, Dietary Influences, and Management

Irritable Bowel Syndrome: Clinical Manifestations, Dietary Influences, and Management

New and Investigational Agents for Irritable Bowel Syndrome

Emerging Pharmacologic Therapies for Constipation-predominant Irritable Bowel Syndrome and Chronic Constipation

Contact Info

Product

Resources

About